title: Activation of peritoneal macrophages during the evolution of type 1 diabetes (insulitis) in streptozotocin-treated mice.
abstract: The effects of lipopolysaccharide (LPS) and desArg9Bradykinin (DBK) on the release of nitric oxide (NO) from macrophages of mice 8, 12 and 18 days after having been treated with low doses of streptozotocin (STZ; 5 × 45 mg/kg) were studied. The results showed that LPS stimulated the release of NO from macrophages of untreated animals by 50% whereas the bradykinin B(1) agonist desArg9Bradykinin (DBK) increased the level of NO by 20%. This increased NO production was totally abolished by incubating the cells with R-954, a selective bradykinin B(1) antagonist. The release of NO from macrophages of STZ-treated mice incubated in the presence of LPS was more marked and reached approximately 220, 300 and 270% respectively from cells collected 8, 12 and 18 days after the STZ treatment. These significant increases were completely blocked by R-954 and were even below control values. Similarly the results showed that DBK stimulated by 50-75% the release of NO from macrophages of STZ-treated mice. The most marked stimulation was noted when the cells were collected 18 days after the treatment of the animals with STZ. Again in this set of experiments the B(1) antagonist completely blocked the release of NO which went even below control values. The results clearly suggest the upregulation of bradykinin B(1) receptors in mouse macrophages in the early phase of STZ-induced diabetes, an event that could even precede the onset of the diabetic hyperglycemia.
authors.affiliation: Departamento de Biología, Escuela de Quimica, Universidad Argentina J F Kennedy, Argentina.
authors.forename: O L
authors.initials: OL
authors.lastname: Catanzaro
authors.forename: D
authors.initials: D
authors.lastname: Dziubecki
authors.forename: E
authors.initials: E
authors.lastname: Labal
authors.forename: P
authors.initials: P
authors.lastname: Sirois
mesh_terms: D000818:Animals; D001786:Blood Glucose / Q000187:drug effects; D001920:Bradykinin / Q000737:chemistry / Q000494:pharmacology; D002478:Cells, Cultured; D003921:Diabetes Mellitus, Experimental / Q000276:immunology*; D003922:Diabetes Mellitus, Type 1 / Q000276:immunology*; D008070:Lipopolysaccharides / Q000494:pharmacology; D008262:Macrophage Activation / Q000276:immunology*; D017737:Macrophages, Peritoneal / Q000166:cytology / Q000187:drug effects / Q000276:immunology*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D009569:Nitric Oxide / Q000276:immunology / Q000378:metabolism; D043783:Receptor, Bradykinin B1 / Q000378:metabolism; D013311:Streptozocin / Q000276:immunology / Q000494:pharmacology
chemical_list: D001786:Blood Glucose; D008070:Lipopolysaccharides; D043783:Receptor, Bradykinin B1; D009569:Nitric Oxide; D013311:Streptozocin; D001920:Bradykinin